CWF19L1 and central nervous system cancer: The analysis results revealed that patients with high expression of CWF19L1 have higher survival rates in the TCGA and CGGA databases (Figure 2B, P < .0001), By immunohistochemical analysis of glioma normal brain tissues (NBTs), low‐grade glioma, and high‐grade glioma, we found that the expression level of CWF19L1 is highest in glioma paracancerous tissue but lowest in high‐grade glioma (Figure S1).